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Summary
Background Human infection with the avian inﬂ uenza A H5N1 virus results in disease with a high fatality rate, 
against which antiviral treatments have limited eﬃ  cacy. We aimed to investigate the safety, pharmacokinetics, and 
therapeutic potential of speciﬁ c polyclonal immunoglobulin equine F(ab’)2 fragments raised against inﬂ uenza 
A/Vietnam/1194/2004 virus (H5N1 subtype) in healthy volunteers.
Methods We did a randomised, double-blind, placebo-controlled, single-centre phase 1 study. In stage 1 (one 
infusion) and stage 2 (ﬁ ve infusions) of the trial, we randomly assigned healthy male volunteers to receive once-
daily intravenous infusions of 0·85 U/kg body weight of F(ab’)2 or once-daily saline placebo. Randomisation was 
done centrally, with one block of four patients and one block for substitutes (three actives, one placebo) in stage 1, 
and two blocks of six patients (ﬁ ve actives and one placebo) and the same block for substitutes in stage 2. The 
primary objective was assessment of the clinical and laboratory safety of F(ab’)2, which was monitored for 22 days 
in the group that received one dose (assessments on days 0–2, 4, 8, 15, and 22) and 33 days in the group that 
received ﬁ ve doses (days 0–6, 8, 10, 12, 19, 26, and 33). A ﬁ nal post-study safety assessment was done at 120 days. 
We also assessed pharmacokinetic outcomes, and assayed haemagglutination and seroneutralisation 
activity. Analysis was done according to intention-to-treat. This trial is registered with ClinicalTrials.gov, 
number NCT02295813.
Findings We enrolled 16 healthy Asian men between Sept 28 and Dec 28, 2012, and randomly assigned 13 to one or 
ﬁ ve doses of F(ab’)2 and three to placebo. F(ab’)2 was well tolerated, and no deaths or serious adverse events 
occurred. Three patients had mild adverse events (one each of blepharospasm, sinusitis, and pyrexia). The pyrexia 
(38°C) was regarded as probably related to the infusion, and resolved after 37 min. Our laboratory assessments of 
blood and urine samples and physical examinations of heart rate, electrocardiogram readings, and weight showed 
no clinically signiﬁ cant safety issues. Mean peak plasma concentrations were 19·3 μg/mL (SD 3·5) with the one 
dose schedule and 23·0 μg/mL (4·5) with the ﬁ ve-dose schedule. F(ab’)2 were still detectable in plasma on average 
up to 5 days after ﬁ ve doses. Haemagglutination inhibition was only increased after the third dose, but in-vitro 
seroneutralisation activity was transiently increased after each of the ﬁ ve doses to concentrations regarded as 
clinically beneﬁ cial in infected patients.
Interpretation F(ab’)2 showed good safety, tolerability, and therapeutic potential for managing of H5N1 exposed patients.
Funding Fab’entech.
Introduction
First detected in 1997, the highly pathogenic avian 
inﬂ uenza A H5N1 subtype virus has caused hundreds of 
cases of inﬂ uenza disease and death in human beings; 
from 2003 to 2014 WHO recorded 668 cases of H5N1 
inﬂ uenza disease, with a consistently high fatality rate, 
despite antiviral treatment, of about 59%.1 Cases have 
been reported from 15 diﬀ erent countries—mainly in 
Asia, but also in the Middle East and Africa. A fatal case of 
a traveller from China also occurred in Canada.2 Infection 
usually follows contact with sick or dead infected poultry 
or products,3,4 and little evidence exists of human-to-
human transmission except for intimate contact in family 
clusters.4–6 However, the high mortality, the emergence of 
travel-related cases, and the knowledge that only a few 
aminoacid mutations are necessary to make virus 
transmission readily airborne,7 ensure that the H5N1 
strain remains a major public-health concern worldwide.
Human infection is associated with severe illness—
symptoms occur generally 2–8 days after exposure 
accompanied by high viral load and raised concentrations 
of proinﬂ ammatory cytokines,4 but anti-H5N1 antibodies 
can only be detected after 14 days.8,9 This combination of 
a rapid inﬂ ammatory and slow immune response might 
account for the high fatality rate associated with H5N1 
infection, even with treatment with adamantanes 
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(amantadine and rimantadine) or neuraminidase 
inhibitors (oseltamivir, peramivir, or zanamivir).10–12 An 
alternative approach would be to increase immune 
protection through passive immunisation before the 
patients have developed their own protective immune 
response, giving additional time for antivirals to treat the 
infection.
Convalescent plasma has been shown to be eﬀ ective in 
severely ill patients,13,14 which suggests that immuno-
globulins could be a viable therapeutic option. Monoclonal 
antibodies were eﬀ ective against H5N1 in preclinical 
studies,15,16 but polyclonal antibodies will probably be more 
beneﬁ cial in the clinical setting. Use of immunoglobulins 
is well established for many human pathological disorders, 
most notably exposure to rabies virus and treatment of 
venomous snake bites.17–19 Polyclonal immunoglobulins 
can be prepared from human or animal serum samples. 
Immunoglobulins prepared from human samples reduce 
the risk of reactions to non-human contaminants and are 
widely used against rabies virus for rabies post-exposure 
prophylaxis. However, for rabies, the restricted availability 
of the human form of the immunoglobulin means that 
the readily available equine version is likely to be used in 
most clinical settings. To reduce allergic reactions to other 
equine proteins in this setting,17 antirabies equine IgG is 
exposed to peptic digestion and the resultant F(ab’)2 
fragments, selectively puriﬁ ed,19 provide equivalent 
eﬃ  cacy with excellent tolerability.18
The equine antirabies IgG puriﬁ cation technology has 
now been applied to produce F(ab’)2 against inﬂ uenza 
H5N1 virus (Fabenﬂ u, Fab’entech development code 
FBF001). Preclinical studies in mice showed that this 
bulk preparation of speciﬁ c anti-H5N1 F(ab’)2 immuno-
globulin fragments (anti-H5N1 F[ab’]2) is non-toxic and 
capable of providing in-vivo neutralisation, with an 
established dose able to provide protection against lethal 
H5N1 viral challenge.20 Here, we report our phase 1 
study of the ﬁ rst application of FBF001 in man, in which 
we aimed to investigate the safety of FBF001, and assess 
its pharmacokinetics and potential eﬃ  cacy against 
H5N1 infection.
Methods
Study design and participants
We did a single-centre, randomised, double-blind, 
placebo-controlled phase 1 study to assess the safety and 
pharmacokinetics of FBF001 in two stages (in stage 1, 
one dose of FBF001 was given for 1 day, in stage 2, one 
dose was given per day for 5 days). The centre was the 
Investigational Medicine Unit of the National University 
Hospital, Singapore.
We screened potential participants who were healthy 
men with a body-mass index of 18–30 kg/m² (inclusive), 
and normal values for blood chemistry and electro-
cardio gram recordings. Exclusion criteria included sero-
positivity for HIV or hepatitis B or C viruses, known 
drug misuse (including detection by blood screening), 
or excessive alcohol consumption. Any medication 
within 14 days before the inclusion or within 5 times the 
elimination half-life or pharmacodynamic half-life of 
that drug was also an exclusion criterion. Each 
participant provided written informed consent before 
enrolment into the study. We obtained approval from 
the local Ethics Committee and the Health Sciences 
Authority of Singapore before participant enrolment, 
and the study was done according to the Declaration of 
Helsinki, Good Clinical Practice guidelines, and local 
regulatory requirements that were current at the time of 
the study.
Randomisation and masking
Enrolled participants were admitted to the Investigational 
Medicine Unit on day 0 and randomly assigned to the 
treatment or placebo groups. A French-agreed contract 
research organisation generated the randomisation list, 
with one block of four patients and one block for 
substitutes (three actives, one placebo) in stage 1, and two 
blocks of six patients (ﬁ ve actives and one placebo) and the 
same block for substitutes in stage 2. Unmasked clinical 
personnel were provided study medications by Fab’entech 
and made up anonymised intravenous bags for the 
masked investigators who were providing treatment. Bags 
were labelled only with treatment number, participant 
number, and participant initials. Participants, data 
analysers, and investigators were masked to treatments. 
Procedures
Pooled horse plasma was puriﬁ ed to obtain highly 
puriﬁ ed F(ab’)2 fragments, as previously described.18,21 
FBF001 was supplied in 5 mL vials containing 6·9 U/mL 
of product. On the basis of eﬀ ective doses in mice that 
have been previously documented,20 we established a 
human equivalent dose of 0·85 U/kg by applying an 






Age (years) 32·0 33·0 (3·6) 32·8 (3·0)
Weight (kg) 63·5 69·6 (12·2) 68·1 (10·4)
Height (cm) 175·0 174·7 (2·9) 174·8 (2·3)





Age (years) 29·5 (7·8) 32·1 (5·4) 31·7 (5·5)
Weight (kg) 74·9 (5·6) 72·3 (12·2) 72·8 (11·2)
Height (cm) 178·5 (10·6) 175·2 (8·1) 175·8 (8·1)
BMI (kg/m²) 23·7 (4·5) 23·5 (3·5) 23·6 (3·4)
Data are mean (SD). BMI=body-mass index.
Table 1: Participant characteristics
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Participants were enrolled into one of two stages of the 
study. The ﬁ rst stage was a safety assessment of one weight-
dependent dose of FBF001 given by intravenous infusion, 
with clinical and laboratory assessments done for 22 days 
(blood samples were taken on days 0, 2, and 22). After 
establishing that this regimen was safe, we enrolled new 
participants for the second stage (after day 8 of the ﬁ rst 
stage) to study the safety and pharmacokinetics of a series 
of intravenous FBF001 infusions (one per day for 5 days).
Medical examinations were done on day 0, before the 
end of hospital admission, and at the last visit of both 
stages of the study. On day 0, blood was taken for clinical 
assessments. On day 1, after a predose blood draw, 
participants in the treatment group received one dose 
(0·85 U/kg) of FBF001 given by intravenous infusion 
with physiological saline (placebo being saline alone) in a 
total volume of 250 mL in 1 h—initially for 12 min at 
50 mL/h, then 24 min at 100 mL/h, and ﬁ nally for 24 min 
at 500 mL/h. In stage 1, one dose was given, in stage 2, 
ﬁ ve consecutive doses were given in the same manner 
with 24 h intervals between doses, and further blood 
draws were made. Plasma was analysed to assess the 
pharmacokinetics and safety of FBF001 over the course 
of the two stages until the ﬁ nal study visits on day 22 in 
stage 1 and day 33 in stage 2.
We developed and validated a sandwich ELISA 
according to the current European23 and US24 guidelines 
to quantify total equine F(ab’)2 in human plasma. Equine 
F(ab’)2 in human plasma samples speciﬁ cally binds to 
plates coated with antihorse IgG F(ab’)2. An antihorse 
IgG F(ab’)2 antibody coupled with peroxidase is used as 
secondary antibody. The total equine F(ab’)2 concentration 
in the samples was calculated and expressed in μg/mL. 
Validation of the method done with human plasma 
samples showed the robustness of the method; 96·2% of 
the samples met the acceptance criteria.23
We stored plasma samples at –80°C until we did the 
analysis of equine F(ab’)2 concentrations, using the 
validated sandwich ELISA. We serially diluted samples to 
obtain results falling on the standard curve from 
1–20 μg/mL, matching the lower and upper limits of 
quantiﬁ cation of the method.
We did descriptive urinalysis and blood chemistry 
analyses at screening and during the monitoring periods 
of both phases, on days 0, 2, and 22 during stage 1, and on 
days 0, 2, 6, and 33 during stage 2. Blood, ketones, protein, 
glucose, and pH were measured in urine samples. 
Concentrations of haemoglobin, haematocrit, red blood 
cell count, mean corpuscular haemoglobin, white blood 
cell count with diﬀ erential (neutrophils, lymphocytes, 
monocytes, eosinophils, and basophils), and platelets 
were measured in blood samples. We also measured 
concentrations of fasting glucose, total protein, urea, 
creatinine, aspartate transaminase, alanine transaminase, 
sodium, alkaline phosphatase, potassium, calcium, 
chloride, total and conjugated bilirubin, γ-glutamyl 
transferase, and creatine phosphokinase. We assessed 
vital signs during both stages, including blood pressure, 
heart rate, oral temperature, and bodyweight.
All participants were monitored for adverse events 
throughout the course of the study, and their severity and 
any relation to the treatment were assessed by the masked 
investigators (classiﬁ ed as mild [no interference with daily 
activities], moderate [moderate interference], or severe 
[major and unacceptable interference], and probable, 
possible, or unlikely related to treatment [as adjudicated by 
the investigator]). The participants remained in the study 
centre for observation from day 0 through day 2 in stage 1, 
and from day 0 through day 6 in stage 2. They then returned 
to the study centre for blood draws and safety assessments 
up to day 22 in stage 1 (days 4, 8, 15, and 22), and day 33 in 
stage 2 (days 8, 10, 12, 19, 26, and 33); we did the ﬁ nal 
poststudy assessments of participants’ wellbeing on day 25 
(SD 3) and day 120 (10) by telephone in stage 1, and at a visit 
to the centre on day 120 (10) in stage 2 (appendix).
Another sign of the purity of F(ab’)2 fragments is their 
inability to activate complement, which needs the 
Description 
(MedDRA term)
Start Finish Duration Intensity Relation with 
treatment?
Stage 1
Event Eyelid twitching 
(blepharospasm)
Day 4 Day 6 2 days Mild Unlikely
Stage 2
Event Febrile reaction 
(general disorders)
Day 3 Day 3 37 min Mild Probable
Event Mild sinusitis 
(infections)
Day 13 Day 23 10 days Mild Unlikely
MedDRA=Medical Dictionary for Regulatory Activities.
 Table 2: Treatment-emergent adverse events
Figure 1: Plasma concentrations of equine F(ab’)2 after one infusion
Concentrations measured in participants over 1 week after infusion of FBF001 or placebo (point of infusion shown 
by the bold arrow).






























See Online for appendix
Articles
288 www.thelancet.com/infection   Vol 15   March 2015
presence of the Fc portion of the IgG molecule.25 In both 
stages of the study, three additional 2 mL blood samples 
were drawn from each participant immediately before, 
immediately after, and 1 h after the end of each infusion 
for identiﬁ cation of complement activation, through the 
measurement of SC5b9 concentrations by ELISA.26 In 
the case of complement activation, the C4a and BD 
portions were analysed to establish the activating 
complement pathway. Descriptive pharmacokinetic 
parameters were analysed with a model-independent 
(non-compartmental) Kinetica program version 4.3.
To ensure that anti-H5N1 F(ab’)2 present in human 
plasma was capable of neutralising H5N1 virus, we did 
haemagglutination27 and seroneutralisation assays with 
Madin-Darby canine kidney (MDCK) cells with two 
methods: ﬁ rst, by use of non-treated human serum or 
plasma to which exogenous F(ab’)2 was added to achieve 
the con centrations expected in F(ab’)2-infused volun teers; 
and second, with plasma from the parti cipants infused 
with F(ab’)2 in stage 2 of the study. All these experiments 
were done at the Institut Pasteur in Cambodia.
Outcomes
The primary objective was to assess the clinical and 
laboratory safety of FBF001 in man; the secondary 
objective was to establish the pharmacokinetic proﬁ le of 
the therapeutic scheme of 5 days repeated intravenous 
doses of FBF001. Calculated pharmacokinetic values 
included the maximum plasma concentration (Cmax) in 
μg/mL, the time at which the maximum plasma 
concentration occurred (Tmax), the half-life in plasmatic 
compartment (t1/2), and the integral of the concentration-
time curve in steady state (AUC(0–24)) or area under the 
plasma concentration curve extrapolated to inﬁ nite time 
(AUC(0–∞)). We also tested the eﬃ  cacy potential of 
FBF001-treated plasma against H5N1 virus.
Statistical analysis
All statistics were descriptive, calculated for treatment 
group and overall. Pharmacokinetic data were analysed 
with Kinetica software version 4.3. Descriptive statistics 
were done with SAS version 8.2.
The trial is registered with ClinicalTrials.gov, number 
NCT02295813.
Role of the funding source
The funder of the study participated in the design and 
analysis of the study. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Sept 28 and Dec 28, 2012, we enrolled four 
participants into stage 1 of the study (three assigned to 
treatment, one to placebo) and 12 into stage 2 (ten assigned 
to treatment, two to placebo). All participants who were 
enrolled received their full assigned treatments and 
completed the study according to schedule. Demographic 
characteristics did not vary between participants (table 1).
No deaths or serious adverse events occurred during 
the study, and only three mild adverse events were 
reported, all from participants who received intravenous 
FBF001 (table 2). These adverse events resolved, and two 
(blepharospasm and mild sinusitis) were thought 
unlikely to be related to the treatment. One event, pyrexia 
(38°C) on day 3 of the 5-day treatment regimen started 
63 min after the infusion and resolved after 37 min and 
was thought to be probably related to the infusion. This 
event did not seem to be associated with any sequelae on 
continued monitoring up to 120 days after infusion.
Figure 2: Plasma concentrations of equine F(ab’)2 after ﬁ ve infusions
Data are mean (SD). Concentrations measured in participants over 1 week after the ﬁ fth infusion of FBF001 (points 
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% AUCextra t½ (h)
Day 1, stage 1
Number of 
participants
3 3 3 3 3 3 3
Mean (SD) 19·3 (3·5) 1·0 (0·0) 203·0 (20) 247·0 (88) 305·0 (76) 20·2 (10·7) 16·8 (7·9)
% CV 18·3% 0% 9·8% 35·7% 25·0% 53·0% 47·1%
Day 1, stage 2
Participants 10 10 10 10 10 10 10
Mean (SD) 19·3 (4·7) 1·0 (0·0) 185·0 (34) 188·0 (34) 241·0(55) 21·2 (6·1) 10·9 (2·4)
% CV 24·5% 0% 18·5% 18·0% 22·7% 28·8% 22·3%
Day 5, stage 2
Participants 10 10 10 10 10 10 Nd
Mean (SD) 23·0 (4·5) 1·0 (0·0) 298·0 (61) 678·0 (213) 804·0 (288) 14·7 (6·4) Nd
% CV 19·4% 0% 20·6% 31·5% 35·9% 43·4% Nd
Cmax=maximum plasma concentration. Tmax=time of maximum plasma concentration. t½=half-life in plasmatic 
compartment. AUC=area under the concentration-time curve. AUC(0–24)=AUC in steady state. AUCt=AUC from 
administration to last observed concentration at time t. AUC(0–∞)=AUC area under the plasma concentration curve 
extrapolated to inﬁ nite time. CV=coeﬃ  cient of variation. Nd=not determined.
 Table 3: Pharmacokinetic data
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Our laboratory assessments of blood and urine samples, 
and physical examinations (heart rate, echocardiogram, 
and bodyweight) did not show any clinically signiﬁ cant 
safety issues (appendix). The infusions were well tolerated, 
and no reactions to the infusions were reported by the 
study volunteers other than the three events described, 
after either one or ﬁ ve doses of FBF001. Safety assessments 
through to day 120 did not show any late reactions.
Baseline measurements of SC5b9 were consistent with 
those found in other studies, and no consistent changes 
occurred from baseline in any group, at any timepoint 
after any dose of placebo or F(ab’)2 in either of the two 
stages of the study (appendix). We did not do any further 
investigations of complement portions.
The expected rapid rise in the plasma equine F(ab’)2 
concentration immediately after infusion of FBF001 was 
followed by a subsequent gradual decrease in plasma 
F(ab’)2 concentration, which happened at similar rates in 
all three participants in the treatment group of stage 1 of 
the study after one dose (ﬁ gure 1). The decline of 
plasmatic concentration after the ﬁ rst infusion in the ten 
participants of stage 2 followed a similar pattern than 
after only one infusion (ﬁ gure 2).
The pharmacokinetic data for plasma equine F(ab’)2 
show how the Cmax and AUC data on day 1 were similar in 
both stages of the study (table 3). AUC0–24 h values were 
similar on the ﬁ rst day of the ﬁ rst stage and the second 
stage (table 3), but increased on day 5 of the second stage, 
after the ﬁ fth consecutive infusion, which suggests  a 
slight accumulation. Notably, a wide range in elimination 
half-life was present in the three participants in stage 1 of 
the study (25·3 h, 15·4 h, and 9·7 h), compared with the 
ten participants in stage 2 (range 7·6–15·7 h; table 3).
This result was supported by the small increase in 
predose values on each of days 3–5, before the new 
infusion on each day. Although the rate of decline from the 
same Cmax after the ﬁ rst dose was similar in stage 2 
(ﬁ gure 2), plasma concentrations remained at 3·3 μg/mL 
or higher throughout the 5-day treatment period. By day 5 
in the second stage, 1 h after giving the ﬁ fth dose, Cmax 
slightly increased compared with one dose, to 23·0 μg/mL 
(table 3), with a delay in clearance, as detectable con-
centrations of equine F(ab’)2 were still present (con-
centrations ≥1·3 μg/mL) in all participants 120 h after the 
last infusion (ﬁ gure 2). 2 weeks after the ﬁ fth dose, equine 
F(ab’)2 was undetectable in nine of the ten participants, 
and only present at low concentrations (1·38 μg/mL) in the 
tenth. In support of this result, the mean ratio of AUCinf on 
day 1 to the AUC0–24 h on day 5 was 1·23, close to the value of 
1, which suggests no or little accumulation of product.
Addition (spiking) of anti-H5N1 F(ab’)2 human serum or 
plasma to achieve the concentrations expected in the 
volunteers was tested for haemagglutination inhibition 
activity and seroneutralisation activity against inﬂ uenza 
A/Vietnam/1194/2004 virus (H5N1 subtype) in MDCK 
cells. Generally, FBF001 concentration, haema gglutination 
inhibition, and neutralising activities had a linear relation 
in a range from 1·25 μg/mL to 320 μg/mL, with some 
diﬀ erences between the assays attributable to basal 
neutralising activity of the unspiked serum samples 
(ﬁ gure 3). Only the highest spiking concentrations 
produced a clear increase in haema gglutination inhibition.
Figure 3: Haemagglutination inhibition and neutralising titres of anti-H5N1 F(ab’)2 in human serum or plasma
Data are means (bars show SD). Concentrations measured in serum samples and plasma spiked with anti-H5N1 F(ab’)2 to achieve the concentrations of F(ab’)2 
expected in patients infused with anti-H5N1 F(ab’)2.
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When the plasmas from the ten volunteers given anti-
H5N1 F(ab’)2 in stage 2 were tested, the same results for 
haemagglutination inhibition were noted (ﬁ gure 4). The 
mean titres before each of the infusions ranged from 
15·2 to 16·8. No increase over this background was noted 
after the ﬁ rst two infusions (at 1 h and 2 h, and 25 h and 
26 h, ﬁ gure 4), but increases were evident after the three 
subsequent infusions. These increases did not persist 
through to the next infusion.
Increases in seroneutralisation activity were more 
obvious (ﬁ gure 4) and occurred after each of the ﬁ ve 
infusions, peaking after the third infusion (when the ﬁ rst 
increase in haemagglutination inhibition was observed). 
Changes in neutralising and haemagglutination inhibition 
activities were consistent with the pharmacokinetics of 
F(ab’)2 (ﬁ gure 4).
Discussion
To our knowledge, our report describes the ﬁ rst use of 
highly puriﬁ ed equine immunoglobulins against H5N1 in 
the form of puriﬁ ed, heat-treated F(ab’)2 fragments in 
human beings to assess the safety and pharmacokinetics 
of these polyclonal immunoglobulins, and the ﬁ rst 
assessment of the potential neutralising eﬃ  cacy of this 
treatment against H5N1 virus in human plasma (panel). 
Similar to the results with puriﬁ ed equine rabies 
immunoglobulin18 or intravenous antivenoms, the 
primary objective of our study was achieved—the infusion 
of a single dose or ﬁ ve consecutive doses at 1 day intervals 
did not cause major side-eﬀ ects, and no apparent reactions 
in the volunteers assessed physically or as clinical 
laboratory parameters.
The high fatality rate of inﬂ uenza A H5N1 infections, 
and the continuing occurrence of such infections makes 
avian inﬂ uenza a persisting public health concern, 
especially with reports of resistance to common antiviral 
therapies,11,12 the occurrence of travel-related cases,2 and 
the potential for the emergence of an airborne-
transmissible strain. The possibility of passive 
immunological therapy has been suggested from clinical 
u se of convalescent plasma in case reports,13,14 and in 
preclinical studies of monoclonal15,16 and polyconal20,32 
antibodies. Drawing on the experience of manufacturers 
of IgG preparations for postexposure prophylaxis to 
rabies virus or intravenous antivenoms, we were able to 
prepare a highly puriﬁ ed equine immunoglobulin 
against H5N1 in the form of puriﬁ ed, heat-treated F(ab’)2 
fragments. This product (FBF001) has been shown to be 
safe and eﬀ ective in mice and eﬃ  cient in neutralising 
H5N1 virus in lethal challenge studies.20
Of the three adverse events reported in our study, only 
a transient increase in temperature during an infusion 
was judged to be related to the treatment, and was mild 
and not associated with any sequelae. The absence of 
complement activation in plasma samples taken 
immediately after infusion is a further sign of the purity 
of the anti-H5N1 F(ab’)2 fragments, which is reliant on 
the absence of Fc contaminants.25 Because Fc receptors 
are implicated in inﬂ ammatory and autoimmune 
reactions, especially when of heterologous origin, the 
absence of Fc in FBF001 contributes to the good 
tolerance of the drug when infused in human beings, as 
in the participants in our study. Long-term use of 
similar products, notably antirabies,18 and antivenom19 
products, has shown that highly puriﬁ ed F(ab’)2 
fragments are generally well tolerated and safe in 
clinical use, and confer crucial medical beneﬁ ts in 
potentially fatal clinical situations. With a consistent 
fatality rate of more than 59% despite antiviral 
therapy,1 H5N1 infections are another situation where 
the use of equine F(ab’)2 might be a realistic alternative 
or complementary therapy.
The pharmacokinetic proﬁ le of FBF001 was similar to 
previous results with other equine F(ab’)2 preparations in 
the scientiﬁ c literature, although there are several 
diﬀ erences between the methods used that make direct 
comparisons diﬃ  cult; eg, variability between the 
bioanalytical methods, the pharmacokinetic calculation 
Figure 4: Haemagglutination inhibition and neutralising titres after ﬁ ve infusions of FBF001
Data are means (bars show SD). Titres measured in patients after ﬁ ve doses of FBF001 at 0 h, 24 h, 48 h, 72 h, and 
96 h (arrows) in study phase 2. 
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models (mono or multicompartmental) chosen, duration 
and frequency of the sampling protocol and the fact that 
the F(ab’)2 fragments are sometimes labelled, which 
could modify the F(ab’)2 pharmacokinetic proﬁ le.33,34 
F(ab’)2 accumulated slightly with the repeated daily dose 
administration over 5 days. The pharmacokinetic results 
suggest, as previously described, a rapid diﬀ usion of 
F(ab’)2 from blood vessel to tissue.35,36 The notion of 
using FBF001, raised in horses against inﬂ uenza 
A/Vietnam/1194/2004 (H5N1 subtype) virus, to treat 
acute H5N1 infection is lent support by the ﬁ nding that 
plasma samples from the volunteers given FBF001 were 
able to neutralise H5N1 virus in vitro in MDCK cells. The 
response to FBF001 infusion was immediate in the 
participants, with evident increases in seroneutralising 
activity already observed after the ﬁ rst infusion, and 
increasing titres with subsequent infusions. Zhou and 
colleagues14 gave three 200 mL infusions of convalescent 
plasma with a neutralising titre of 80 to successfully 
provide passive immunity to a patient with H5N1 avian 
inﬂ uenza. With an assumption of a total body volume of 
2·8 L of plasma, this corresponds to a rough titre of 
5·7 in their patients, so the ﬁ nding of titres up to 12 in 
our FBF001-infused volunteers suggests that this product 
has the potential for therapeutic use in clinical settings.
Increases in haemagglutination inhibition against H5N1 
virus were less obvious until after the third infusion, but 
this inhibition was against a high background of activity in 
untreated plasma. This high activity might have been 
caused by the presence of non-speciﬁ c or cross-reactive 
antibodies, or both, acquired from previous exposure to 
other inﬂ uenza A viruses. Although the use of historic 
equine serums as post-exposure prophylaxis for rabies 
infection or as treatment of envenomation in human 
beings is not new, it has been hampered by the frequency 
and severity of adverse events associated with their use.17 
The development of highly puriﬁ ed F(ab’)2 fragments from 
equine plasma was shown to substantially improve the 
safety and tolerability of polyclonal immunoglobulins of 
equine origin, with little eﬀ ect on the immunotherapeutic 
eﬀ ects.18,19 Subsequently, many forms of highly puriﬁ ed 
equine F(ab’)2 have become commercially available for use 
against a range of potentially fatal human disorders 
including diseases such as rabies, and for the treatment of 
snakebite and scorpion stings. As new diseases emerge, 
such as H5N1, and potentially the variant H7N9 which has 
emerged in China,37 the rapid development of highly 
puriﬁ ed speciﬁ c polyclonal immunoglobulins will 
probably be an essential method to treat these new 
infections. The process is well established, and the 
preparation and puriﬁ cation of highly puriﬁ ed F(ab’)2 
fragments has been proven on an industrial scale.18 The 
safety of highly puriﬁ ed equine F(ab’)2 for rabies has been 
proven with widespread use, and their pharmacotherapeutic 
eﬃ  cacy is shown in actual clinical use in patients exposed 
to rabies.29 For ethical reasons (in view of the highly 
pathogenic nature of the virus) and the low number of 
cases and unpredictability of epidemiology, phase 2 and 3 
clinical trials for H5N1 have not been started with F(ab’)2. 
Fab’entech intends to conﬁ rm the eﬃ  cacy and safety of the 
F(ab’)2 fragments by postapproval monitoring based on 
case data collection issued from a speciﬁ ed surveillance 
programme, as speciﬁ ed in an agreed pharmacovigilance 
and risk management plan. Because few cases will be 
reported, the postauthorisation monitoring will correspond 
essentially to observational, non-randomised, single-arm 
studies.
Our study shows that proven technologies and 
industrial processes used to produce commercial highly 
puriﬁ ed F(ab’)2 against diseases such as rabies, can be 
applied to a new medical problem—highly pathogenic 
avian H5N1 infection in human beings. Plasma from 
volunteers given FBF001 had neutralisation activity 
against H5N1 virus consistent with protection against 
infection in previous case reports.
All these data suggest the potential of FBF001 as a new 
therapeutic approach in the clinical management of patients 
infected with H5N1. The product is already available for 
compassionate use or emergency stock in at-risk countries 
such as Singapore and Cambodia, and similar approaches 
are under discussion in other concerned countries.
Panel: Research in context
Systematic review
As might be expected for a phase 1 study, few reported data 
directly relate to our study of anti-H5N1 F(ab’)2 to treat avian 
inﬂ uenza infections. We searched PubMed without date or 
language restrictions on Nov 28, 2014, with the search terms 
“human avian inﬂ uenza” and “passive immunotherapy”, which 
identiﬁ ed 28 publications, most of which were preclinical reports 
of studies in birds or mice, typically with monoclonal antibodies, 
but also the ﬁ rst report of the successful treatment of an infected 
patient with convalescent plasma.13 When we did a search that 
used the terms “equine F(ab’)2” AND “human” we identiﬁ ed 
several reports about the development of such products, the 
most relevant describing the safety of puriﬁ ed equine F(ab’)2 
when used to treat human exposures to snake bites (254 cases),28 
rabies postexposure prophylaxis (6464 cases in adults and 
children),29 viper bites (268 cases in adults and children),30 and 
scorpion stings (1534 cases in adults and children),31 which were 
consistent in showing that severe reactions to the treatments 
were rare and resolved.
Interpretation
To our knowledge, this study is the ﬁ rst to use puriﬁ ed equine 
F(ab’)2 raised against avian inﬂ uenza in doses high enough to 
achieve neutralising activity in human beings associated with 
protection. The safety and tolerability were consistent with the 
scientiﬁ c literature for puriﬁ ed equine F(ab’)2 raised against 
other pathogens including venoms and viruses. Use of these 
anti-H5N1 F(ab’)2 as a complement to current antiviral 
therapies could help to improve the prognosis for H5N1 
infections, which currently have a 59% fatality rate. 
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